Publication | Open Access

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

Bi 2536Novel Plk-1 InhibitorMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung Cancer